Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apimeds Pharmaceuticals UsAPUS +0.93%14 EV-to-EBIT is -0.43 as of Jul. 21, 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 144927.39% on this metric.
Apimeds Pharmaceuticals Us (AMEX:APUS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Apimeds Pharmaceuticals Us's Enterprise Value for the quarter that ended in Mar. 2026 was $29.63 Mil.
Apimeds Pharmaceuticals Us's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us EV-to-EBIT Related Terms
Apimeds Pharmaceuticals Us EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's EV-to-EBIT falls into.
Apimeds Pharmaceuticals Us's current Enterprise Value is $16.98 Mil.
Apimeds Pharmaceuticals Us's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us (APUS) has a EV-to-EBIT of -0.43 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Apimeds Pharmaceuticals Us' EV-to-EBIT too high?
Apimeds Pharmaceuticals Us' current EV-to-EBIT is -0.43. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' EV-to-EBIT compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 690 companies for EV-to-EBIT. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current EV-to-EBIT is -0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current EV-to-EBIT of -0.43. The current EV-to-EBIT is -0.43. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current EV-to-EBIT is -0.43 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
